The Honourable Dalton McGuinty, Premier of Ontario, Canada, to Receive BIO International Leadership Award

Wed May 6, 2009 12:49pm EDT

* Reuters is not responsible for the content in this press release.

WASHINGTON--(Business Wire)--
The Honourable Dalton McGuinty, Premier of Ontario, Canada., will receive the
Biotechnology Industry Organization`s (BIO) second annual International
Leadership Award for his strong commitment to the development and growth of the
biotechnology industry in Ontario, Canada. 

The award honours individuals who have shown a strong commitment to advancing
biotechnology through policy mechanisms that facilitate and strengthen a country
or region`s innovation frameworks. The award will be presented to the Honourable
Dalton McGuinty at the 2009 BIO International Convention. 

"Premier McGuinty was chosen for this award based on his exemplary record of
promoting the biotechnology industry and innovation in the life sciences in
Ontario," said James C. Greenwood, president and CEO, BIO. "I strongly believe
that our industry will continue to thrive in Ontario under his leadership." 

"I want to thank the Biotechnology Industry Organization for this great honour,"
said Premier McGuinty. "Every day, researchers in Ontario are building on our
strong reputation for leadership in the life sciences. It's their hard work
that's led to discoveries with the power to transform lives and our economy. Our
government will continue to fund their efforts so Ontario is the home of the
next generation of breakthroughs, the next generation of businesses and the next
generation of jobs." 

"Premier McGuinty has shown strong leadership and a commitment to innovation and
biotechnology," said Peter Brenders, President and CEO of BIOTECanada, Canada's
national association representing the biotechnology sector. "BIOTECanada has
seen clear support for the commercialization of biotechnology and life sciences
innovations in the past year and we believe work Premier McGuinty has begun is
escalating Ontario into a global biotechnology hub." 

Under McGuinty`s leadership, Ontario has pledged over $3.2-billion dollars to
support research and innovation through Ontario`s Innovation Agenda; the
creation of the Ontario Institute for Cancer Research; programs such as
Ontario`s Biopharmaceutical Investment Program; clean fuel initiatives; and
programs to support talent retention and R&D -- including a new $100-million
competition for genomics and gene-related research: The Global Leadership Round
in Genomics and Life Sciences. 

In 2005, McGuinty first led a group of business and researcher representatives
to the 2005 BIO International Convention in Philadelphia, signaling the start of
great growth in Ontario`s biotech industry. 

With 25 research and academic hospitals employing 10,000 scientists, clinical
investigators and other researchers conducting $850 million in research
annually, Ontario is the largest hub of biomedical activity in Canada and the
third largest biomedical research centre in North America. 

Ontario`s life sciences industry employs more than 43,000 people at more than
850 companies which generate more than $14 billion in annual revenues. 

Each year, the BIO International Convention draws industry leaders from
approximately 48 states and 60 countries. This year, the Convention program will
feature 167 sessions in 22 breakout session tracks. Sessions will address the
most pressing issues facing biotech today, including healthcare pricing and
access, capital formation and partnering strategies in a tight credit
environment, and climate change and biofuels. 

In addition, this year`s BIO Exhibition will cover will cover an estimated
176,000 net sq. ft. and host more than 1,800 exhibitors. 

To register for the BIO International Convention, please visit
http://convention.bio.org/. 

Advanced media registration will be available online through May 8, 2009. To
register, please visit http://convention.bio.org/media. 

The BIO International Convention helps to support BIO programs and initiatives.
BIO works throughout the year to create a policy environment that enables the
industry to continue to fulfill its vision of bettering the world through
biotechnology innovation. For more information on the global event for
biotechnology, including program and housing information, please visit
http://convention.bio.org/. 

2009 BIO International Convention Social tagging & Social Media

Be included in official convention coverage: Tag your convention related
content, blog posts, photos and videos with bio09
Twitter with us: hashtag #bio09
Follow us on Twitter:http://twitter.com/BIOconvention
Listen to our podcasts:http://biotech-now.org
Join us on FaceBook:http://www.facebook.com/group.php?gid=12611785695
Connect with us on LinkedIn:http://www.linkedin.com/groups?gid=35214
Visit our YouTube channel:http://www.youtube.com/user/BIOchannel
View our photo albums on Flickr:http://www.flickr.com/photos/biophotos/

Upcoming BIO Events

BIO-LES Business Development Basics Course
May 15-17, 2009
Atlanta, GA 

BIO-LES Advanced Business Development Course
May 15-17, 2009
Atlanta, GA 

BIO Executive Presentation Workshop
May 17, 2009
Atlanta, GA 

BIO Human Resources Conference
May 17-19, 2009
Atlanta, GA 

2009 BIO International Convention
May 18-21, 2009
Atlanta, GA 

BioEquity Europe
June 9-10, 2009
Munich, Germany 

World Congress on Industrial Biotechnology & Bioprocessing
July 19-22, 2009
Montreal, Quebec, Canada 

About BIO

BIO represents more than 1,200 biotechnology companies, academic institutions,
state biotechnology centers and related organizations across the United States
and in more than 30 other nations. BIO members are involved in the research and
development of innovative healthcare, agricultural, industrial and environmental
biotechnology products. BIO also produces the BIO International Convention, the
world`s largest gathering of the biotechnology industry, along with
industry-leading investor and partnering meetings held around the world. 



BIO
Tracy Krughoff
202-312-9274
http://convention.bio.org

Copyright Business Wire 2009

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.